U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.

IF 33.7 1区 医学 Q1 Medicine Mmwr Recommendations and Reports Pub Date : 2024-08-08 DOI:10.15585/mmwr.rr7304a1
Antoinette T Nguyen, Kathryn M Curtis, Naomi K Tepper, Katherine Kortsmit, Anna W Brittain, Emily M Snyder, Megan A Cohen, Lauren B Zapata, Maura K Whiteman
{"title":"U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.","authors":"Antoinette T Nguyen, Kathryn M Curtis, Naomi K Tepper, Katherine Kortsmit, Anna W Brittain, Emily M Snyder, Megan A Cohen, Lauren B Zapata, Maura K Whiteman","doi":"10.15585/mmwr.rr7304a1","DOIUrl":null,"url":null,"abstract":"<p><p>The 2024 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by persons who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during January 25-27, 2023. The information in this report replaces the 2016 U.S. MEC (CDC. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR 2016:65[No. RR-3]:1-103). Notable updates include 1) the addition of recommendations for persons with chronic kidney disease; 2) revisions to the recommendations for persons with certain characteristics or medical conditions (i.e., breastfeeding, postpartum, postabortion, obesity, surgery, deep venous thrombosis or pulmonary embolism with or without anticoagulant therapy, thrombophilia, superficial venous thrombosis, valvular heart disease, peripartum cardiomyopathy, systemic lupus erythematosus, high risk for HIV infection, cirrhosis, liver tumor, sickle cell disease, solid organ transplantation, and drug interactions with antiretrovirals used for prevention or treatment of HIV infection); and 3) inclusion of new contraceptive methods, including new doses or formulations of combined oral contraceptives, contraceptive patches, vaginal rings, progestin-only pills, levonorgestrel intrauterine devices, and vaginal pH modulator. The recommendations in this report are intended to serve as a source of evidence-based clinical practice guidance for health care providers. The goals of these recommendations are to remove unnecessary medical barriers to accessing and using contraception and to support the provision of person-centered contraceptive counseling and services in a noncoercive manner. Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services. This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health care providers about contraceptive use.</p>","PeriodicalId":51328,"journal":{"name":"Mmwr Recommendations and Reports","volume":"73 4","pages":"1-126"},"PeriodicalIF":33.7000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11315372/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mmwr Recommendations and Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15585/mmwr.rr7304a1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

The 2024 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by persons who have certain characteristics or medical conditions. These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during January 25-27, 2023. The information in this report replaces the 2016 U.S. MEC (CDC. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR 2016:65[No. RR-3]:1-103). Notable updates include 1) the addition of recommendations for persons with chronic kidney disease; 2) revisions to the recommendations for persons with certain characteristics or medical conditions (i.e., breastfeeding, postpartum, postabortion, obesity, surgery, deep venous thrombosis or pulmonary embolism with or without anticoagulant therapy, thrombophilia, superficial venous thrombosis, valvular heart disease, peripartum cardiomyopathy, systemic lupus erythematosus, high risk for HIV infection, cirrhosis, liver tumor, sickle cell disease, solid organ transplantation, and drug interactions with antiretrovirals used for prevention or treatment of HIV infection); and 3) inclusion of new contraceptive methods, including new doses or formulations of combined oral contraceptives, contraceptive patches, vaginal rings, progestin-only pills, levonorgestrel intrauterine devices, and vaginal pH modulator. The recommendations in this report are intended to serve as a source of evidence-based clinical practice guidance for health care providers. The goals of these recommendations are to remove unnecessary medical barriers to accessing and using contraception and to support the provision of person-centered contraceptive counseling and services in a noncoercive manner. Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services. This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health care providers about contraceptive use.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2024 年美国使用避孕药具的医疗资格标准。
2024 年美国避孕药具使用医疗资格标准》(U.S. MEC)包括对具有某些特征或医疗条件的人使用特定避孕方法的建议。2023 年 1 月 25 日至 27 日,美国疾病预防控制中心在佐治亚州亚特兰大市审查了科学证据并召开了全国专家会议,之后更新了这些针对医疗保健提供者的建议。本报告中的信息取代了 2016 年美国医疗资格标准(CDC.2016 年美国避孕药具使用医疗资格标准》。MMWR 2016:65[No.RR-3]:1-103)。值得注意的更新包括:1)增加了对慢性肾病患者的建议;2)修订了对具有某些特征或医疗条件(即、母乳喂养、产后、流产后、肥胖、手术、深静脉血栓或肺栓塞(无论是否接受抗凝治疗)、血栓性疾病、浅静脉血栓、瓣膜性心脏病、围心肌病、系统性红斑狼疮、HIV 感染高风险、肝硬化、肝肿瘤、镰状细胞病、实体器官移植,以及与用于预防或治疗 HIV 感染的抗逆转录病毒药物发生药物相互作用);3)纳入新的避孕方法,包括新剂量或新配方的复方口服避孕药、避孕贴片、阴道环、纯孕激素药片、左炔诺孕酮宫内节育器和阴道 pH 调节器。本报告中的建议旨在为医护人员提供循证临床实践指导。这些建议的目的是消除获取和使用避孕药具的不必要医疗障碍,并支持以非胁迫方式提供以人为本的避孕咨询和服务。医疗服务提供者应始终考虑每位寻求避孕服务者的个人临床情况。本报告无意取代针对个别患者的专业医疗建议;必要时,患者应就避孕药具的使用向其医疗服务提供者寻求建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Mmwr Recommendations and Reports
Mmwr Recommendations and Reports PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
36.00
自引率
0.00%
发文量
3
期刊介绍: The MMWR series of publications is published by the Office of Science, Centers for Disease Control and Prevention (CDC), U.S. The MMWR Recommendations and Reports contain in-depth articles that relay policy statements for prevention and treatment in all areas in the CDC’s scope of responsibility (e.g., recommendations from the Advisory Committee on Immunization Practices).
期刊最新文献
CDC Program Evaluation Framework, 2024. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. U.S. Selected Practice Recommendations for Contraceptive Use, 2024. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1